Brendan advises life sciences companies on collaborations, license agreements, joint ventures, carve-out transactions, in-license and out-license transactions, co-development and co-commercialization arrangements, manufacturing and supply agreements, distribution agreements, royalty monetization transactions and other strategic relationships across the life sciences sector.

Brendan has particular experience advising founders, emerging life sciences companies and venture capital investors on structuring and negotiating the foundational intellectual property arrangements on which new life sciences companies or new therapeutic programs are built. This includes transactions involving pharmaceutical company spin-outs, in-licenses from universities and other research institutions, and cross-border licensing and collaboration arrangements. Brendan structures these arrangements with attention to their impact on future financings, strategic collaborations, sublicenses, acquisitions and other downstream diligence events.

Brendan also has significant experience with life sciences transactions involving AI-enabled drug discovery and computational approaches to research, development and diagnostics. He advises clients on collaborations and licensing arrangements involving the use of machine learning models, proprietary data, software tools and experimental biology to identify, validate and advance therapeutic and diagnostic products and research platforms.

Prior to joining Gunderson Dettmer, Brendan was an attorney in the Palo Alto office of Cooley LLP.

Brendan holds a J.D. from the University of Chicago Law School and a B.S., with honors, in Computer Engineering from the University of Illinois at Urbana-Champaign. He is admitted to practice in California.